Latest Nintedanib Stories
RnRMarketResearch.com adds “Nintedanib (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
For U.S. Media Only RIDGEFIELD, Conn., Sept.
SAN DIEGO, Aug. 5, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S.
For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.
SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc.
RIDGEFIELD, Conn., July 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
Results from Boehringer Ingelheim, InterMune and IPFnet clinical trials discussed CHICAGO, May 18, 2014 /PRNewswire-USNewswire/ -- WHO: The Pulmonary Fibrosis
- Growing in low tufty patches.